EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access · CC BY 4.0

Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study

Xiangnan Niu, Shiwei Sun, Wenjuan Fan, Peng Yue, Wei Yao, Yue Wang, Xiaoqian Deng, Fuyu Guo, Yangang Zhang iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0303440 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Xiangnan Niu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Carcinoma, Neuroendocrine, Nomograms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuroendocrine carcinoma (NEC) is a rare yet potentially perilous neoplasm. The objective of this study was to develop prognostic models for the survival of NEC patients in the genitourinary system and subsequently validate these models. A total of 7125 neuroendocrine neoplasm (NEN) patients were extracted. Comparison of survival in patients with different types of NEN before and after propensity score-matching (PSM). A total of 3057 patients with NEC, whose information was complete, were extracted. The NEC influencing factors were chosen through the utilization of the least absolute shrinkage and selection operator regression model (LASSO) and the Fine & Gary model (FGM). Furthermore, nomograms were built. To validate the accuracy of the prediction, the efficiency was verified using bootstrap self-sampling techniques and receiver operating characteristic curves. LASSO and FGM were utilized to construct three models. Confirmation of validation was achieved by conducting analyses of the area under the curve and decision curve. Moreover, the FGS (DSS analysis using FGM) model produced higher net benefits. To maximize the advantages for patients, the FGS model disregarded the influence of additional occurrences. Patients are expected to experience advantages in terms of treatment options and survival assessment through the utilization of these models.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, NeuroendocrineNomogramsHumansMaleFemaleMiddle AgedRetrospective StudiesAgedUrogenital NeoplasmsPrognosisAdultROC Curve

Autor:innen und Institutionen

  • Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, China.
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Urology, Taiyuan Central Hospital of Shanxi Medical University, Taiyuan, China.
  • Department of Gynecology, Xian No. 1 Hospital, Xi'an, China.
  • Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.

ORCID-Profile: Yangang Zhang

Zitieren

APA

Niu, X., Sun, S., Fan, W., Yue, P., Yao, W., Wang, Y., Deng, X., Guo, F., & Zhang, Y. (2024). Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study. PLOS ONE. https://doi.org/10.1371/journal.pone.0303440

Vancouver

Niu X, Sun S, Fan W, Yue P, Yao W, Wang Y, et al. Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study. PLOS ONE. 2024. doi:10.1371/journal.pone.0303440

BibTeX
@article{Niu2024,
  author = {Niu, Xiangnan and Sun, Shiwei and Fan, Wenjuan and Yue, Peng and Yao, Wei and Wang, Yue and Deng, Xiaoqian and Guo, Fuyu and Zhang, Yangang},
  title = {Development and validation of nomograms to predict survival of neuroendocrine carcinoma in genitourinary system: A population-based retrospective study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0303440}
}
Kostenlos starten →